We analyzed 99 patients' serum samples for concentrations of a new antiarrhythmic agent, flecainide acetate, by fluorescence polarization immunoassay (FPIA) and "high-performance" liquid chromatography (HPLC). Within-day and between-day coefficients of variation at concentrations in the low and high ends of the therapeutic range were <7% for HPLC and <9% for FPIA. There was no statistical difference in the mean (±SD) concentrations of the clinical serum samples measured by the two methods (607 ± 334 g/L by HPLC, 602 ± 344 tg/L by FPIA), but results by each differed by a mean of 0.13%. FPIA and HPLC measurements correlated significantly (r = 0.98, P <0.05), and were linearly related (slope = 0.970, intercept = 13 g/L) as assessed by orthogonal regression. Both assay methods produced similar concentration measurements and were sufficiently accurate and precise to be used in therapeutic drug monitoring.
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Flecaimde acetate is an anti-arrhythmic agent recently approved by the FDA for suppression of ventricular arrhythmias. Because of the wide range of fiecainide acetate concentrations seen in serum of patients exhibiting >90% suppression of ventricular ectopic beats (200 to 1000 g/L) (1-3), and the apparent increased risk of proarrhythmic effects at serum concentrations >1000 ng/mL (4), monitoring of drug concentrations will likely play a role in the management of patients treated with this drug. To assessthe performance of methods for measuring flecainide acetate in the serum of patients, we compared fluorescence polarization immunoassay (FPIA) measurements with those obtained by "highperformance" liquid chromatography (HPLC) with fluorescence detection (5).
Materials and Methods
Reagents. HPLC-grade chemicals were used for the chromatographic procedure and extraction process. Flecainide acetate (lot no. 45) and the internal standard, N-(2-piperidylmethyl)-2,3-bis(2,2,2-trifluoroethoxy)benzamide hydrochloride (lot no. 6), were obtained from Riker Laboratories, St. Paul, MN. Reagents, calibrators, and controls for the FPIA method were obtained from Abbott Diagnostics Division, Irving, TX.
Instrumentation. The standards, controls, and all sera analyzed by HPLC were extracted by passing them through a 3-mL octyl (C8) solid-phase extraction column (Analytichem, Harbor City, CA), as described in detail elsewhere (5). This method has an average extraction efficiency of about 75% and is specific for separating flecainide from its metabolites. We then measured the flecainide acetate concentrations in the resulting extraction eluent by reversed-phase Associates, Milford, MA), particle size 10 zzn. We detected the drug by using a Spectroflow 980 fluorescence detector (Kratos Analytical, Ramsey, NJ), with an excitation wavelength of 300 mu and an emission cutoff filter of 370 am. The mobile phase consisted ofa mixture of acetonitrile and phosphoric acid, 60 mLfL (35/65 by vol) pumped at a flow rate of 2 mL/min by a Constametric ifi pump (Laboratory Control Data, Riviera Beach, FL). Quantification of flecainide acetate by HPLC was based on its peak height relative to that of the internal standard, a positional isomer offlecainide. We also analyzed the serum samples for flecainide acetate by FPIA with the TDx assay system (Abbott Diagnostics Division) according to the manufacturer's recommendations.
Precision and accuracy. Both assay methods utilized a sixpoint standard curve constructed with serum standards supplemented with flecainide acetate to final concentrations of 0, 100, 300, 600, 1000, and 1600 pg/L (HPLC) or 0, 100, 250, 500, 1000, and 1500 g/L (FPIA).
For the HPLC method, we calculated a standard curve each day. Within-day precision of the HPLC method was assessed by assaying seven replicates of low (150 g/L) and high (1000 pg/L) serum controls relative to the therapeutic range. Between-day precision was assessed by seven single determinations of each of the two controls over seven days. The lower limit of detection of the HPLC method was 50 g/ L, as defined by a signal-to-noise ratio of 4:1.
For the FPIA system, we assessed the within-day precision of this method (after calibration on day 1) by making 10 determinations of serum controls at low (150), medium (600), and high (1200 .tg/L) concentrations. Between-day precision was assessed by 10 single determinations of each of the three controls over 10 days. The lower limit of detection of the FPIA method for flecainide acetate was also 50 .tgIL, the minimum measurable concentration that could be distinguished from zero with 95% confidence (6) . Accuracy was determined by the percent relative error (RE) for all serum controls and was calculated by the following equation.
Clinical specimens.
Serum samples were obtained from 99 patients receiving flecainide acetate for the treatment of ventricular arrhythmias. The samples were stored at -20 #{176}C until analysis in single measurements by HPLC and duplicate measurements by FPIA (results reported as the mean). For FPIA, samples with flecainide acetate concentrations >1500 ug/L were diluted with an equal volume of drug-free serum and re-measured, and the results were multiplied by two to obtain the actual concentration in the original serum. All clinical samples were analyzed over a two-day period.
Statistics. Concentrations of the drug in serum, determined by FPIA and HPLC for patients' samples, were analyzed for normality of distribution by the KolmogorovSmirnov test, then compared by a paired t-test by using the RS-1 statistics package (7) as implemented on a VAX 8600 mainframe computer. To determine the linear relationship between the two assay methods, we used weighted orthogonal least-squares regression (8). The correlation of the two methods was assessed by using Pearson's correlation coefficient (9) . Statistical significance was defined as P <0.05.
Results and Discussion
Representative chromatograms from the HPLC method are shown in Figure 1 . The accuracy and precision data for the HPLC method are summarized in Table 1 . Within-and between-day CVs were <6% and <7%, respectively. Similarly, Table 2 summarizes measures of the accuracy and precision of the FPIA method. Larger CVs were observed for both within-and between-day measurements of the low (150 g/L) control than for the medium and high controls by the FPIA method, reflecting less precision at concentrations just below the therapeutic range. Nevertheless, the within-and between-day CVs were <9% for all controls used in both methods. Similarly, the accuracy for each method is evi- 
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Within-day (n = 10) The mean (± SD) serum concentration measured by the FPIA method was not statistically different from that measured by the HPLC method (602 ± 344 vs 607 ± 334 g/L, respectively, n = 93). The mean percent error (-0.13%) of the FPIA method relative to the HPLC method indicates a slight tendency of the FPIA method to underpredict measurements, on the average, as compared with the HPLC method.
The minor differences observed between the two methods may be due to random measurement error. Another possible source of discrepancy between the two assays could be the construction of the standard curves, which involved standards and controls of different sources for each method. This could have introduced measurement bias throughout the concentration range for the unknown clinical samples. In addition, the HPLC standard curve reflects the linear relation between flecainide acetate concentration and the flecainide acetate/internal standard peak-height ratio, whereas the FPIA standard curve is based on a nonlinear function of millipolarization units and flecainide acetate concentration. Different curve-fitting functions may also contribute to the measurement discrepancies of the two methods. However, because of the small y-intercept ( Figure 2 ) and the minimal mean percent en-or (-0.13%), we consider the standard curve construction to be, at most, a minor source of discrepancy.
Another potential source of difference between FPIA and HPLC is the degree of interference from endogenous compounds (e.g., bilirubin) or from concomitantly administered preparations. Interference with the FPIA assay is reportedly <10% in the presence of high concentrations of protein (100 g/L), triglyceride (18.00 g/L), bilirubin (150 mg/L), cholesterol (6000 mg/L), or hemoglobin (10 g/L) in serum (6) . Also, the FPIA cross reacts by <0.1% with several cardiac drugs that could potentially be administered in conjunction with flecainide, and with the main flecainide metabolites, meta-O-dealkylated flecainide and the meta-O-dealkylated lactam of flecainide (6) . After usual doses of flecaimde acetate to produce flecainide concentrations of 200-1600 g/L in serum, these flecainide metabolites are present in serum of patients with normal or depressed renal function at <50 g/ L (11) . Given the relatively small concentration of metabolites in serum and a low percentage of cross reactivity, analysis for flecainide by FPIA would be appropriate for most patient populations receiving therapeutic doses of the drug.
Several attributes of the FPIA method make it an attractive procedure, in comparison with HPLC, for therapeutic drug monitoring. The sample volume of 50 zL is much less than the 1 mL used in the HPLC method and requires no preparation, in contrast to the extraction required for the HPLC method. Additional advantages include a relatively fast turnaround time and the requirement for minimal technician skill.
In summary, this assay comparison indicates that the FPLA and the HPLC methods measure similar concentrations of flecainide acetate in serum. Both methods are sufficiently accurate and precise in measuring serum concentrations of this drug in the range of 70 to 1600 g/L.
